Related Experiment Video
Updated: Aug 26, 2026

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
Hyperkalemia in fatal MDMA ('ecstasy') toxicity
Abstract:
3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is an amphetamine synthetic analog widely used as an recreational drug. Acute and severe toxic effects following MDMA ingestion include hyperthermia, arrhythmias, rhabdomyolisis, disseminated intravascular coagulation, hepatotoxicity and even death. Recently, we treated a patient in whom hyperkalemia, in the absence of renal failure, aggravated the expected toxic complications of MDMA, becoming the immediate cause of his death.
Insights
3,4-Methylenedioxymethamphetamine (MDMA) can cause severe toxicity. In a patient without kidney issues, hyperkalemia worsened MDMA complications, leading to death.
Area of Science:
- Toxicology
- Pharmacology
- Cardiology
Background:
- 3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is a recreational amphetamine analog.
- MDMA use is associated with severe toxic effects including hyperthermia, arrhythmias, rhabdomyolysis, and hepatotoxicity.
Observation:
- A patient experienced severe toxic complications after MDMA ingestion.
- Hyperkalemia was noted in the patient, despite the absence of renal failure.
Findings:
- Hyperkalemia significantly aggravated the expected toxic effects of MDMA.
- Hyperkalemia was identified as the direct cause of the patient's death.
Implications:
- This case highlights hyperkalemia as a critical, potentially fatal complication of MDMA toxicity.
- Clinicians should consider monitoring potassium levels in patients with severe MDMA intoxication, especially when renal function is preserved.
More Related Videos
Related Concept Videos
Toxidromes: Clinical Features
Drug Toxicity: Dose-Dependent Reactions
Heart Failure Drugs: Inotropic Agents
Drug Toxicity: Overview
Drug toxicity: Idiosyncratic Reactions
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

